Browse by Journal Title

2024

Altered enhancer-promoter interaction leads to MNX1 expression in pediatric acute myeloid leukemia with t(7;12)(q36;p13).
Weichenhan, D., Riedel, A., Sollier, E., Toprak, U.H., Hey, J., Breuer, K.H., Wierzbinska, J.A., Touzart, A., Lutsik, P., Bähr, M., Östlund, A., Nilsson, T., Jacobsson, S., Waraky, A., Behrens, Y.L., Göhring, G., Schlegelberger, B., Steinek, C., Harz, H., Leonhardt, H., Dolnik, A., Reinhardt, D., Bullinger, L., Palmqvist, L., Lipka, D.B. and Plass, C.
Blood Advances 8 (19): 5100-5111. 8 October 2024

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.
Rücker, F.G., Bullinger, L., Cocciardi, S., Skambraks, S., Luck, T.J., Weber, D., Krzykalla, J., Pozek, E., Schneider, I.J., Corbacioglu, A., Gaidzik, V.I., Meid, A., Aicher, S., Stegelmann, F., Schrade, A., Theis, F., Fiedler, W., Salih, H.R., Wulf, G.G., Salwender, H.J., Schroeder, T., Götze, K.S., Kühn, M.W.M., Lübbert, M., Schlenk, R.F., Benner, A., Thol, F.R., Heuser, M., Ganser, A., Döhner, H. and Döhner, K.
Blood Advances 30 September 2024 (In Press)

2023

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology.
Klever, M.K., Sträng, E., Hetzel, S., Jungnitsch, J., Dolnik, A., Schöpflin, R., Schrezenmeier, J.F.F., Schick, F., Blau, O., Westermann, J., Rücker, F.G., Xia, Z., Döhner, K., Schrezenmeier, H., Spielmann, M., Meissner, A., Melo, U.S., Mundlos, S. and Bullinger, L.
Blood Advances 7 (21): 6520-6531. 14 November 2023

Retained functional normal and preleukemic HSCs at diagnosis are associated to good prognosis in DNMT3Amut NPM1mut AMLs.
Donato, E., Correia, N.C., Andresen, C., Karpova, D., Würth, R., Klein, C., Sohn, M., Przybylla, A., Zeisberger, P., Rothfelder, K., Salih, H.R., Bonig, H., Stasik, S., Röllig, C., Dolnik, A., Bullinger, L., Buchholz, F., Thiede, C.D., Hübschmann, D. and Trumpp, A.
Blood Advances 7 (6): 1011-1018. 28 March 2023

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen, G.J.J.E., Baumgartner, F., Heider, M., Patra, U., Holz, M., Braune, J., Kaiser, M., Schäffer, I., Bamopoulos, S.A., Ramberger, E., Murgai, A., Ng, Y.L.D., Demel, U.M., Laue, D., Liebig, S., Krüger, J., Janz, M., Nogai, A., Schick, M., Mertins, P., Müller, S., Bassermann, F., Krönke, J., Keller, U. and Wirth, M.
Blood Advances 7 (4): 469-481. 28 February 2023

Disruption of stem cell niche-confined R-spondin 3 expression leads to impaired hematopoiesis.
Kurtova, A.V., Heinlein, M., Haas, S., Velten, L., Dijkgraaf, G.J.P., Storm, E.E., Kljavin, N.M., Boumahdi, S., Himmels, P., Herault, A., Mancini, A.G., Koeppen, H., Dail, M., Yan, M., Zhang, J., Koch, U., Radtke, F., Modrusan, Z., Metcalfe, C., Piskol, R. and de Sauvage, F.J.
Blood Advances 7 (4): 491-507. 28 February 2023

2022

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner, H., Weber, D., Krzykalla, J., Fiedler, W., Wulf, G.G., Salih, H.R., Lübbert, M., Kühn, M., Schroeder, T., Salwender, H., Götze, K.S., Westermann, J., Fransecky, L., Mayer, K., Hertenstein, B., Ringhoffer, M., Tischler, H.J., Machherndl-Spandl, S., Schrade, A., Paschka, P., Gaidzik, V.I., Theis, F., Thol, F.R., Heuser, M., Schlenk, R.F., Bullinger, L., Saadati, M., Benner, A., Larson, R.A., Stone, R.M., Döhner, K. and Ganser, A.
Blood Advances 6 (18): 5345-5355. 27 September 2022

A complex proinflammatory cascade mediates the activation of HSCs upon LPS exposure in vivo.
Demel, U.M., Lutz, R., Sujer, S., Demerdash, Y., Sood, S., Grünschläger, F., Kuck, A., Werner, P., Blaszkiewicz, S., Uckelmann, H.J., Haas, S. and Essers, M.
Blood Advances 6 (11): 3513-3528. 10 June 2022

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K.C., Scheid, C., Keller, U., Hose, D. and Bassermann, F.
Blood Advances 6 (2): 515-520. 25 January 2022

2021

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers, N., Duell, J., Fitzgerald, D., Kerkhoff, A., Noerenberg, D., Kaebisch, E., Acker, F., Fuhrmann, S., Leng, C., Welslau, M., Chemnitz, J., Middeke, J.M., Weber, T., Holtick, U., Trappe, R., Pfannes, R., Liersch, R., Spoer, C., Fuxius, S., Gebauer, N., Caillé, L., Geer, T., Koenecke, C., Keller, U., Claus, R., Mougiakakos, D., Mayer, S., Huettmann, A., Pott, C., Trummer, A., Wulf, G., Brunnberg, U., Bullinger, L., Hess, G., Mueller-Tidow, C., Glass, B., Lenz, G., Dreger, P. and Dietrich, S.
Blood Advances 5 (13): 2707-2716. 13 July 2021

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Bohl, S.R., Schmalbrock, L.K., Bauhuf, I., Meyer, T., Dolnik, A., Szyska, M., Blätte, T.J., Knödler, S., Röhner, L., Miller, D., Kull, M., Langer, C., Döhner, H., Letai, A., Damm, F., Heckl, D., Bullinger, L. and Krönke, J.
Blood Advances 5 (9): 2391-2402. 11 May 2021

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
Heuser, M., Heida, B., Büttner, K., Wienecke, C.P., Teich, K., Funke, C., Brandes, M., Klement, P., Liebich, A., Wichmann, M., Neziri, B., Chaturvedi, A., Kloos, A., Mintzas, K., Gaidzik, V.I., Paschka, P., Bullinger, L., Fiedler, W., Heim, A., Puppe, W., Krauter, J., Döhner, K., Döhner, H., Ganser, A., Stadler, M., Hambach, L., Gabdoulline, R. and Thol, F.
Blood Advances 5 (9): 2294-2304. 11 May 2021

Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice.
Li, C., Goncalves, K.A., Raskó, T., Pande, A., Gil, S., Liu, Z., Izsvák, Z., Papayannopoulou, T., Davis, J.C., Kiem, H.P. and Lieber, A.
Blood Advances 5 (5): 1239-1249. 9 March 2021

Deregulated expression of circular RNAs in acute myeloid leukemia.
Lux, S., Blätte, T.J., Gillissen, B., Richter, A., Cocciardi, S., Skambraks, S., Schwarz, K., Schrezenmeier, H., Döhner, H., Döhner, K., Dolnik, A. and Bullinger, L.
Blood Advances 5 (5): 1490-1503. 9 March 2021

2020

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn, N., Terzer, T., Sträng, E., Dolnik, A., Cocciardi, S., Panina, E., Corbacioglu, A., Herzig, J., Weber, D., Schrade, A., Götze, K., Schröder, T., Lübbert, M., Wellnitz, D., Koller, E., Schlenk, R.F., Gaidzik, V.I., Paschka, P., Rücker, F.G., Heuser, M., Thol, F., Ganser, A., Benner, A., Döhner, H., Bullinger, L. and Döhner, K.
Blood Advances 4 (24): 6342-6352. 22 December 2020

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.
Völker, L.A., Kaufeld, J., Miesbach, W., Brähler, S., Reinhardt, M., Kühne, L., Mühlfeld, A., Schreiber, A., Gaedeke, J., Tölle, M., Jabs, W.J., Özcan, F., Markau, S., Girndt, M., Bauer, F., Westhoff, T.H., Felten, H., Hausberg, M., Brand, M., Gerth, J., Bieringer, M., Bommer, M., Zschiedrich, S., Schneider, J., Elitok, S., Gawlik, A., Gäckler, A., Kribben, A., Schwenger, V., Schoenermarck, U., Roeder, M., Radermacher, J., Bramstedt, J., Morgner, A., Herbst, R., Harth, A., Potthoff, S.A., von Auer, C., Wendt, R., Christ, H., Brinkkoetter, P.T. and Menne, J.
Blood Advances 4 (13): 3093-3101. 14 July 2020

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Völker, L.A., Kaufeld, J., Miesbach, W., Brähler, S., Reinhardt, M., Kühne, L., Mühlfeld, A., Schreiber, A., Gaedeke, J., Tölle, M., Jabs, W.J., Özcan, F., Markau, S., Girndt, M.., Bauer, F., Westhoff, T.H., Felten, H., Hausberg, M., Brand, M., Gerth, J., Bieringer, M., Bommer, M., Zschiedrich, S., Schneider, J., Elitok, S., Gawlik, A., Gäckler, A., Kribben, A., Schwenger, V., Schoenermarck, U., Roeder, M., Radermacher, J., Bramstedt, J., Morgner, A., Herbst, R., Harth, A., Potthoff, S.A., von Auer, C., Wendt, R., Christ, H., Brinkkoetter, P.T. and Menne, J.
Blood Advances 4 (13): 3085-3092. 14 July 2020

2019

Longitudinal assessment of clonal mosaicism in human hematopoiesis via mitochondrial mutation tracking.
Lareau, C.A., Ludwig, L.S. and Sankaran, V.G.
Blood Advances 3 (24): 4161-4165. 23 December 2019

Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.
Nasri, M., Mir, P., Dannenmann, B., Amend, D., Skroblyn, T., Xu, Y., Schulze-Osthoff, K., Klimiankou, M., Welte, K. and Skokowa, J.
Blood Advances 3 (1): 63-71. 8 January 2019